# EU-1-21-1529_public-assessment-report_20210218_20210218_vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
29 January 2021
EMA/94907/2021
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
COVID-19 Vaccine AstraZeneca
Common name: COVID-19 Vaccine (ChAdOx1-S [recombinant])
Procedure No. EMEA/H/C/005675/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
7
1.1. Submission of the dossier
7
1.2. Steps taken for the assessment of the product
9
2. Scientific discussion
12
2.1. Problem statement
12
2.1.1. Disease or condition
12
2.1.2. Epidemiology and risk factors
12
2.1.3. Aetiology and pathogenesis
12
2.1.4. Clinical presentation and diagnosis
13
2.1.5. Management.
13
2.2. Quality aspects
15
2.2.1. Introduction
15
2.2.2. Active substance
15
2.2.3. Finished medicinal product
25
2.2.4. Discussion on chemical, and pharmaceutical aspects
35
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
39
2.2.6. Recommendations for future quality development
41
2.3. Non-clinical aspects
42
2.3.1. Pharmacology
42
2.3.2. Pharmacokinetics
46
2.3.3. Toxicology
47
2.3.4. Ecotoxicity/environmental risk assessment
49
2.3.5. Discussion on non-clinical aspects
49
2.3.6. Conclusion on the non-clinical aspects
54
2.4. Clinical aspects
54
2.4.1. Introduction
54
2.4.2. Pharmacokinetics
59
2.4.3. Pharmacodynamics
59
2.4.4. Discussion on clinical pharmacology
71
2.4.5. Conclusions on clinical pharmacology
73
2.5. Clinical efficacy
73
2.5.1. Main studies
74
2.5.2. Pooled efficacy analysis
77
2.5.3. Discussion on clinical efficacy
115
2.5.4. Conclusions on clinical efficacy
123
2.6. Clinical safety
124
2.6.1. Methodology
124
2.6.2. Patient exposure
124
2.6.3. Adverse events
125
2.6.4. Serious adverse event/deaths/other significant events
135
EMA/94907/2021
Page 2/181
